Although our study paves the way for new prospective studies on the RAD51B promoter methylation’s predictive role in patients with NSCLC treated with anti-PD-1, the retrospective design and small sample size are not neglectable limitations. The gene discussed is RAD51B; the disease is non-small cell lung carcinoma.